AGENDA - SATURDAY, AUGUST 16

8:00am-5:00pm
ISPE Board of Directors Meeting (Dansk Design Center)
(Open to ISPE members; notify staff if you plan to attend)

Noon-5:00pm
Registration (Auditorium Foyer/Bella Center)

PRE-CONFERENCE EDUCATIONAL SESSION
1:00-5:00pm
Introduction to Pharmacoepidemiology (Room 18/19)
[Registration required; included as part of the full meeting registration]

  Chair: Andrew McAfee
  Ralph Edwards, Spontaneous Reporting
  Andrew McAfee, Cohort Studies
  Lolkje de Jong-van den Berg, Case-Control Studies
  Daniel Fife, FISPE, Confounding

5:30-7:00pm
Journal Club (Room 18/19)

5:00-7:00pm
Student Meet and Greet (TBA)
Organized by the ISPE Student Council

BELLA CENTER
All pre-ICPE courses, ICPE committee, council and SIG meetings will be held at the Bella Center, Center Boulevard 5, Copenhagen, Denmark.

BADGES
All attendees at ICPE 2008 must wear their name badges to all events.
A badge will be needed for admission to meeting related functions, such as the scientific sessions, the exhibit/poster hall, and social events. Badges will be included in the registration packet material. In some cases, tickets for admission will be required.

Badge Legend

- Student – YELLOW
- New Member – BLUE
- One Day Attendees – RED

2008
ISPE’s Third Asian Meeting
(Asian Conference on Pharmacoepidemiology/ACPE-Korea 2008)
Convened in conjunction with the Korean Society for Pharmacoepidemiology and Risk Management (KoPERM)

- November 3-5, 2008
- Convention Center, Grand Hilton Seoul, Korea

2009
ISPE Mid-Year Meeting 2009

- April 25-27, 2009
- Karolinska University Hospital
- Stockholm, Sweden

25th Anniversary International Conference on Pharmacoepidemiology & Therapeutic Risk Management

- August 16-19, 2009
- Rhode Island Convention Center
- Providence, Rhode Island, USA

Visit the ISPE website www.pharmacoepi.org for meeting updates and information.
PRE-CONFERENCE EDUCATIONAL SESSIONS

8:30am-Noon
Regulatory Epidemiology/Public Health Decision Making* (Auditorium 10)

Educational Objectives
- Understand the intent and structure of regulation to protect the Public Health
- Appreciate the challenges of decision making with weak data
- Know about practical approaches typically chosen by regulators
- Recognize the challenges epidemiology faces to provide sufficient information for public health decision making
- Have an overview of world wide challenges for drug regulatory agencies and variation in approaches
- Know about current strategies to strengthen regulation in the face of these challenges

Chair: Gerald Dal Pan
Gerald Dal Pan, US FDA, Regulation & Challenges of Decision Making with Weak Data
June Raine, EMEA, Regulatory Decision Making Approaches in Europe
Stephen Evans, London School of Tropical Medicine, An Epidemiologist’s View of Public Health Decision Making
Ralph Edwards, WHO Collaborating Centre for International Drug Monitoring, Global Perspective on Regulatory Utilization of Pharmacovigilance Data

8:30am-Noon
Introduction to Drug Utilization/Health Services Research’ (Auditorium 11)

Educational Objectives
- To explain the definition and scope of the eclectic discipline of Drug Utilization Research within the context of Pharmaco-epidemiology
- To motivate researchers providing international cross-national comparisons of national drug utilization data to cooperate on the collection of a minimal dataset of reliable and comparable drug utilization data in their country, in terms of volume, expenditures and quality of drug use
- To explain the process of developing and validating prescribing quality indicators.
- To give an applied overview of methods useful for drug policy research (time series analysis)

Co-Chairs: Robert Vander Stichele & Julie Zito
Marit Rønning, Classifying and Quantifying Drug Use for Cross National Comparison. The Anatomical Therapeutic Chemical Classification and the Defined Daily Dose Methodology
Monique Elseviers, Strengths and Limitations of Drug Utilization Research Methods
Morten Andersen, Assessing Validity of Prescribing Quality Indicators
Colin Dormuth, Time Trend Analyses for Program Evaluation

8:30am-12:00pm
Students Only Special Skills Workshop: How Do I Get There? (Room 18/19)
[Included as part of full meeting registration, sign-up required]
- Organized by ISPE Student Council

Co-Chairs: Imran Syed Haider & Sengwee Darren Toh
Speakers:
Susana Perez Gutthann, FISPE, RTI Health Solutions
Brian L. Strom, FISPE, University of Pennsylvania
Miriam CIM Sturkenboom, Erasmus University Medical Center
Claudia S. Cabrera, AstraZeneca
Frank de Vries, Universiteit Utrecht
Mara McAdams, US Food & Drug Administration

Topics include (but not limited to)
- Potential career paths upon graduation
- Factors that drive your decision
- What are recruiters looking for in a candidate
- Advice to current students

Noon-1:30pm
Lunch on your own.
### PRE-CONFERENCE EDUCATIONAL SESSIONS

#### 1:30-5:30pm

**Advanced Topics in Pharmacoepidemiology** *(Auditorium 10)*

**Chair:** Sebastian Schneeweiss, FISPE

- **Doug Altman,** *Indirect Comparison of Randomized Clinical Trial Results*
- **Ken Rothman,** FISPE, *Effect Measure Modification*
- **Lawrence McCandless,** *Bayesian Adjustments for Unmeasured Confounders in Epidemiologic Studies*
- **John Seeger,** *Transparency in the Use of Propensity Scores*

*Admission by ticket only. Tickets will be included in registration materials for those who registered for these sessions.*

#### 1:30-5:30pm

**Introduction to Risk Management** *(Auditorium 11)*

**Co-Chairs:** Elizabeth Andrews, FISPE, & Carla van Bennekom

- **Elizabeth Andrews,** FISPE, *Introduction to Therapeutic Risk Management*
- **Stella Blackburn,** *Implementation and Experiences in the EU*
- **Carla van Bennekom,** *Examples of Risk Management Programs and Evaluations*
- **Judith Jones,** FISPE, *Developing Risk Management Plans*

---

**Health.**

**It’s what we care about.**

Wyeth is a global leader in pharmaceutical, biotechnology and vaccine products. We are united in a common mission with shared values and unique talents that allow us to achieve our ambitious vision: to lead the way to a healthier world.

**Wyeth is proud to be a Gold Sponsor of the 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.**

The growing epidemiology group at Wyeth addresses questions of natural history of disease, drug safety, and drug utilization. We provide consultation to colleagues in research and development, pharmacovigilance, risk management, and medical affairs.

To learn more about opportunities at Wyeth, visit us online at: [www wyeth com careers](http://www.wyeth.com/careers)

Equal Opportunity Employer M/F/D/V
## AGENDA - MONDAY, AUGUST 18

**7:30-8:15am**  
Poster Session A Set-up (Hall A1)

**7:30am-6:00pm**  
Registration (Auditorium Foyer)

**7:30am-5:00pm**  
Speakers’ Ready Room (Room 7)

**8:00am-6:00pm**  
Exhibits/Posters (Hall A1)

### 8:15-9:45am

**OPENING SESSION** (Auditorium 10-12)

- Welcome  
  Jesper Hallas, Chair, Scientific Program Committee  
  Jens Peter Balling, Chair, Local Host Committee

- Presidential Address  
  Yola Moride, FISPE, ISPE President

- Keynote Address  
  Mads Melbye, Statens Serum Institut, Copenhagen, *When An Entire Country is a Cohort*

### 10:30am-12:00pm

**CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

**Applied Methods** (Auditorium 10)  
**Moderators:** Til Stürmer, FISPE, & Morten Andersen

**10:30am**  
**An Algorithm To Identify Antidepressant Users with a Diagnosis of Depression from Prescription Data** [1]  
Helga Gardarsdottir, Toine CG Egberts, Liset van Dijk, Miriam Stirkenboom, Eibert R Heerdink. (Netherlands)  
*Student Award Recipient – Best Methods Abstract*

**10:45am**  
**Active Safety Surveillance of Influenza Vaccines: Potential for Using Large Insurers’ Claims** [2]  
Kristen Moore, M Miles Braun, Grace Lee, Martin Kuldorff, Najat Ziyadeh, Dale Burwen, Robert Ball, Sukhminder Sandhu, Richard Platt, Jeffrey Brown. (United States)

**11:15am**  
**Impact of Patient Visit Frequency and Physician Activity on the Weighted Analysis of a Cross Sectional Survey** [4]  
Patrick Blin, Nathalie Schmidely, Bruno Bregman, Florence Mercier, Coralie Poncet, Francoise Roudot-Thoraval. (France)

**11:30am**  
**Re-Evaluation of SCORTEN, a Predictive Score of Mortality for Patients with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)** [5]  
P Sekula, A Dunant, M Mockenhaupt, M Schumacher, A Sidoroff, S Halevy, JP Fagot, for the RegiSCAR-Study Group. (Germany)

**11:45am**  
**A Validation Study of Self Reported Antiretroviral Use within a Clinical Cohort of HIV Positive Patients** [6]  
Emily S Brouwer, Sonia Napravnik, Amanda H Corbett, Joseph J Eron. (United States)
Pfizer, Inc. discovers, develops, manufactures, and markets leading prescription medicines for humans and animals.

With 2007 actual spending of $8.1 billion in research & development (R&D), Pfizer has the industry’s largest pharmaceutical R&D organization.

Our search for new treatments spans hundreds of research projects across forty-eight major disease groups in 10 therapeutic areas.

We build our success on the innovation, skills, and entrepreneurial spirit of each of our colleagues.

Every day we help 38 million patients, utilize the skills of more than 12,000 medical researchers, and work in partnership with governments, individuals, and other payers for healthcare to treat and prevent illnesses – adding both years to life, and life to years.

The Epidemiology Group at Pfizer partners with development teams to bring new medicines to patients by providing epidemiologic research strategies throughout the development continuum.

We are committed to the conduct of research meeting the highest scientific and ethical standards to assess the benefits and risks of our medicines.

Pfizer Epidemiology is proud to support the 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management and welcomes the opportunity for the open exchange of scientific ideas and research findings in order to advance the science of pharmacoepidemiology and risk management.
AGENDA - MONDAY, AUGUST 18

Cardiovascular: Effect Modification, Genetics and Beyond
(Auditorium II)

**Moderators:** Anke Ilse Maitland & Jeanne Dieleman

10:30am

- **Association of Cardiovascular Drugs and NOSIAP with QTc Prolongation and Sudden Cardiac Death** [7]
  
  Charlotte van Noord, Albert-Jan LHJ Aarnoudse, Miriam CJM Sturkenboom, Sabine MJM Straus, Jacqueline CM Witteman, Bruno HCH Stricker. (Netherlands)

10:45am

- **Renin-Angiotensin System Polymorphisms, Use of ACE Inhibitors and the Risk of Myocardial Infarction** [8]
  
  Olaf H Klungel, Diane van Wieren de Wijer, Anthonius de Boer, Abraham A Kroon, Paul Schifers, Peter W de Leeuw, Bruce M Psaty, Cornelia van Duijn, Bruno HCH Stricker, Anke Ilse Maitland van der Zee. (Netherlands)

11:00am

- **The Influence of Reduced Activity of Cytochrome P450 CYP2C9 and Vitamin K Epoxide Reductase Complex Subunit 1 on Anticoagulation with Acenocoumarol or Phenprocoumon** [9]
  
  Martina Teichert, Bruno Stricker, Loes Visser. (Netherlands)

11:15am

- **The Effect of Seven Genetic Variants on the Response to Clopidogrel** [10]
  
  Ankie M Harmszé, Jochem W van Werkum, Vera H Deneer, Henk J Ruven, Olaf H Klungel, Chris M Hackeng, Jurrien M ten Berg, Anthonius de Boer. (Netherlands)

11:30am

- **Risk of Hospitalization for Angioedema with Combination Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers** [11]
  
  Jennifer B Christian, Anne L Hume, Charles B Eaton, Lan Jiang, Peter D Friedmann, Kate L Lapanne. (United States)

11:45am

- **Duration of Clopidogrel Treatment after Acute Myocardial Infarction with or without Percutaneous Coronary Intervention** [12]
  
  Rikke Sorensen, Gunnar H Gislason, Steen Z. Abdistrom, Mette Madsen, Tina K Schramm, Fredrik Folke, Morten L. Hansen, Lars Kober, Christian Torp-Pedersen. (Denmark)

To Err is Human, To Improve is Divine (2)
(Auditorium 12)

**Moderators:** Judith Jones, FISPE, & Michael Lewis, FISPE

10:30am

- **Effect of a Computerized Physician Order Entry (CPOE) System on Prescribing Errors and Preventable Adverse Drug Events (pADEs)** [13]
  
  J van Doormaal, R Zaal, P Mol, J Kosterink, F Haaijer-Ruskamp, A Egberts, A Lenderink, P van den Bemt. (Netherlands)

10:45am

- **Increasing Exposure to Drug-Drug Interactions between 1992 and 2005 in People Aged ≥ 55 Years** [14]
  
  Matthijs J Becker, Loes E Visser, Teun van Gelder, Albert Hofman, Bruno HCH Stricker. (Netherlands)

11:00am

- **Systematic Review Examining the Prevalence and Nature of Prescribing Errors in Hospital Inpatients** [15]
  
  Penny Lewis, Kathryn Bell, Tim Dornan, David Taylor, Mary P Tully, Darren Ashcroft. (United Kingdom)

11:15am

- **Identifying, Understanding, and Overcoming Barriers to Medication Error Reporting in Hospitals in Nova Scotia, Canada** [16]
  
  Nicole R Hartnell, Neil J MacKinnon, Ingrid Sketris, Steven M Smith, Mark Fleming. (Canada)

11:45am

- **Compliance with Clinical Monitoring Guidelines for Novantrone® (Mitoxantrone) in Multiple Sclerosis** [17]
  
  Donnie Funch, Heather Norman, Judy Wong, Randy Bennett, Jill Hillier, Ahmad Al-Sabbagh, John Seeger. (United States)
AGENDA - MONDAY, AUGUST 18

**Analgesics / Anti-inflammatory Drugs (2) (Room 18/19)**

**Moderators:** James Lewis & Gunnar Gislason

10:30am

- COX-2 Inhibitors Associated with Lower Risk of Hospitalization for Gastrointestinal Events Compared to Traditional NSAIDs Plus Proton Pump Inhibitors [18]
  Michiel W van der Linden, Ernst J Kuipers, Myrthe P Sukel, Ron M Herings, Sabine Gaugris. (Netherlands)

10:45am

- Interactions between Warfarin and Fluoroquinolones, Sulfonamides, and Azole Antifungals and the Risk of Serious Gastrointestinal Bleeding [19]
  Hedi Schelleman, Warren B Bilker, Colleen M Brensinger, Xiaoyan Han, Stephen E Kimmel, Sean Hennessy. (United States)

11:15am

- Use of Oral Glucocorticoids and Risk of Atrial Fibrillation/Flutter - A Population Based Case-Control Study [20]
  Christian Christiansen, Steffen Christensen, Frank Mehnert, Henrik Toft Sørensen. (Denmark)

11:30am

- Does the Varied Use of NSAIDs Explain the Differences in the Risk of Myocardial Infarction? [21]
  Tjeerd P van Staa, Stephan Rietbrock, Efrosini Setakis, Hubert GM Leufkens. (United Kingdom)

11:45am

- Increased Mortality and Cardiovascular Morbidity Associated with Use of Non-Steroidal Anti-Inflammatory Drugs in Chronic Heart Failure [22]
  Gunnar H Gislason, Jeppe N Rasmussen, Emil L Fosboll, Tina K Schramm, Morten L Hansen, Fredrik Folke, Rikke Sørensen, Soren Rasmussen, Steen Z Abildstrom, Christian Torp-Pedersen. (Denmark)

---

**What does Lilly provide to patients?**

**Answers.**

We impact lives by delivering answers to some of the world’s toughest health care questions. And, with over a century of experience behind our name, there is no one better prepared than Eli Lilly and Company to tackle these questions and the challenges of our changing industry.

We have laid the foundation for continued success with a rich pipeline of best-in-class, first-in-class pharmaceutical products and a collaborative culture that supports people in reaching their greatest potential. It is through the diverse perspectives and accomplishments of our people that we are able to touch the lives of patients by providing the medicines that will enable them to lead longer, healthier lives.

Today and in the future, Lilly will provide “Answers That Matter.”

[www.lilly.com](http://www.lilly.com)

---

Lilly

Answers That Matter.
AGENDA - MONDAY, AUGUST 18

Adherence (Room 20)

Moderators: Brian Quilliam & Bernard Vryens

10:30am

<table>
<thead>
<tr>
<th>Trends in Adherence to Secondary Prevention Medications in Post-Myocardial Infarction Medicare Beneficiaries [23]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Niteesh K Choudhry, Soko Setoguchi, Raisa Levin, Wolfgang C Winkelmayer, William H Shrank. (United States)</td>
</tr>
</tbody>
</table>

10:45am

<table>
<thead>
<tr>
<th>Does Guideline Adherence Yield Better Outcomes? A Study on the Treatment of Acute Myocardial Infarction Based on Routine Data [24]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jutta Küpper-Nybelen, Lothar Heymans, Martin Hellmnich, Reinhard Griebenow, Ingrid Schubert. (Germany)</td>
</tr>
</tbody>
</table>

11:00am

<table>
<thead>
<tr>
<th>Initiation and Persistence of Warfarin or Aspirin Treatments in Chronic Atrial Fibrillation: Do the Appropriate Patients Receive Stroke Prophylaxis? [25]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arlene M Gallagher, Stephan Rietbrock, Jonathan Plumb, Jteerd P van Staa. (United Kingdom)</td>
</tr>
</tbody>
</table>

11:15am

<table>
<thead>
<tr>
<th>Is Adherence to Prescription Guidelines a General Trait or Dependent of Drug Type? A Multilevel Logistic Regression Analysis in Scania, Sweden [26]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Henrik Ohlsson, Juan Merlo. (Sweden)</td>
</tr>
</tbody>
</table>

11:30am

<table>
<thead>
<tr>
<th>Persistence among Osteoporotic Patients Having Started Weekly Oral Bisphosphonate Therapy [27]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odile Sheehy, Christian Kindundu, Martin Barbeau, Jacques LeLorier. (Canada)</td>
</tr>
</tbody>
</table>

11:45am

<table>
<thead>
<tr>
<th>Primary Medication Adherence in Patients Receiving Electronic Prescriptions [28]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael A Fischer, Margaret Stedman, Joyce Lii, Christine Vogeli, Joel S Weissman. (United States)</td>
</tr>
</tbody>
</table>

12:15-1:30pm

Lunch/Poster Session A/Exhibits (Hall A1)

Poster Walks: • Drug Utilization • Biologics

ISPE Committee/Council Meetings

- Open to all participants. • Lunches will be available in meeting rooms
  - Public Policy Committee (Room 16)
  - Student Council (Room 17)
  - Fellowship & Awards Committee (Room 18A)
  - Development Committee (Room 18B)
  - Finance Committee (Room 23)

Genentech IN BUSINESS FOR LIFE

Genentech is a leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. We commit ourselves to high standards of integrity in contributing to the best interests of patients, the medical profession, our employees and our communities, and to seeking significant returns to our stockholders, based on the continual pursuit of scientific and operational excellence.

A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products directly in the United States: Avastin™ (bevacizumab), Tarceva™ (erlotinib), Rituxan® (Rituximab), Herceptin® (Trastuzumab), Lucentis® (Ranibizumab), Xolair® (Omalizumab), RAPITIVA® (efalizumab), TNKase™ (Tenecteplase), Activase® (Alteplase, recombinant), Cathflo™ Activase® (Alteplase, Nutropin® [somatropin (rDNA origin) for injection], Nutropin AQ® [somatropin (rDNA origin) injection], Pulmozyme® (dornase alfa, recombinant).

The Genentech Epidemiology group provides evidence-based epidemiology strategy, expertise and data to optimize Genentech’s therapeutic molecule selection, development, and commercialization. Our activities range from estimating disease incidence and prevalence, describing clinical course of disease and real world treatment practices and providing epidemiological context for adverse events, to collaborating in the design, analysis, and reporting of observational studies and patient registries.

CONTACT INFORMATION
Genentech, Inc. – 1 DNA Way, South San Francisco, CA 94080-4990
Phone: (650) 225-1000 • www.gene.com
AGENDA - MONDAY, AUGUST 18

1:30-3:00pm
CONCURRENT SESSIONS: CONTRIBUTED PAPERS

Pregnancy Exposures and Adverse Outcomes: From Erection to Resurrection (Auditorium 10)

**Moderators:** Susan Roberts & Elizabeth Andrews, FISPE

1:30pm

[D] Impact of Prior Prenatal Testing on Birth Defect Prevalence in Pregnancy Exposure Registries [29]
Deborah Covington, Susan S Roberts, Laura McKay. (United States)

1:45pm

Mette Nørgaard, Lars Pedersen, Mette Gislum, Rune Erichsen, Kirstine K Søgaard, Henrik C Schönheyder, Henrik T Sørensen. (Denmark)

2:00pm

[D] Antifungal Medications and the Risk of Hypoplastic Left Heart Syndrome [31]
Carol Louik, Martha M Werler, Allen A Mitchell. (United States)

2:15pm

[D] Lamotrigine and Orofacial Clefts [32]
Janneke Jentink, Helen Doll, Maria Loane, Joan Morris, Lolkje TW De Jong van den Berg. (Netherlands)

2:30pm

[D] Selective Serotonin Reuptake Inhibitor Use and Risk of Gestational Hypertension [33]
Sengwee Toh, Allen A Mitchell, Christina D Chambers, Carol Louik, Martha M Werler, Sonia Hernandez-Diaz. (United States)

2:45pm

[D] Stillbirth and Early Neonatal Death Risk Is Reduced in Those Using Analogue Compared with Those Using Human Insulin [34]
Corinne de Vries, Julia Snowball, David Russell-Jones, Annie Hutchison. (United Kingdom)

Methods for Pharmacovigillance (Auditorium II)

**Moderators:** Andrzej Czarnecki, FISPE, & Juergen Dinger

1:30pm

[D] Patterns of Adverse Event Reporting for Four Members of the Angiotensin II Receptor Blockers Class of Drugs: Revisiting the Weber Effect [35]
Mara A McAdams, Kate Gelpiner, Laura A Governale, Lynette Swartz, Tarek A Hammad, Gerald J Dal Pan. (United States)

1:45pm

[D] Exploring the Relationship of a Statistical Alerts and Clinical Relevance [36]
Sheila R Weiss Smith, Stephanie Chung, Deborah A Sturpe, Guarrav Desphande, Bryan Hayes, Victor Gogolak. (United States)

2:00pm

[D] The Index of Blame: Agreement between Subjective vs. Objective Designation of ‘Suspect’ Drugs in Pharmacovigilance [37]
Alan M Hochberg, Ronald K Pearson. (United States)

2:15pm

[D] Drug-Drug ADR Screening in Spontaneous Reports as a Tool for Detecting Clustered Reporting and Brand Name Confusion [38]
Johanna Strandell, Niklas G Noren, Andrew Bate, Ralph J Edwards. (Sweden)

2:30pm

[D] Signal Detection of Rosuvastatin by a Novel Data Mining Approach in Health Insurance Claims Database [39]
Nam Kyong Choi, Yoonsoo Chang, Seokyung Hahn, Byung Joo Park. (Republic of Korea)

2:45pm

[D] Web-Based Intensive Monitoring, a Promising Method for Active Surveillance of New Drugs [40]
Kees van Grootheest, Linda Harmark, Ingrid Oosterhuis, Eugene P van Puijenbroek. (Netherlands)
**Psychotropics: Utilization and Risks** (Auditorium 12)

**Moderators:** Dan Mines & Julie Zito

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
</tr>
</thead>
</table>
| 1:30pm | **Factors Associated to the Initiation of Psychoactive Drug Use in a Sample of Healthy Workers in France: Results of the VISAT Study** [41]  
Olivia Boeuf Cazou, Jean Claude Marquie, Maryse Lapeyre-Mestre. (France) |
| 1:45pm | **Selective Prescribing and Channeling of Antipsychotics: Baseline Data from the French Prospective Cohort Study on Schizophrenia** [42]  
L. Abenhaim, F. Rouillon, H. Verdoux, B. Falissard, J. Benichou, M. Rossignol, P. Blin, F. Depont, B. Astruc. (France) |
| 2:00pm | **Better Persistence on Treatment with Escitalopram Compared with Citalopram** [43]  
Larry Ereshefsky, Nicolas Despigel, Khaled Maman, Clement Francois, Delphine Saragoussi. (France) |
| 2:15pm | **No Increase in Risk of Road Traffic Accidents after Prescriptions of Mood Stabilizers** [44]  
Jørgen G Bramness, Svetlana Skurtveit, Ineke Neutel, Jørg Mortland, Anders Engeland. (Norway) |
| 2:30pm | **Patterns of Patient Monitoring after Initiation of Antidepressant Medications** [45]  
Joshua J Gagne, Philip S Wang, Sebastian Schneeweiss. (United States) |
| 2:45pm | **Fatal and Non-Fatal Pneumonia Associated with Atypical and Typical Antipsychotic Use in Elderly Patients** [46]  
Giànluca Trifiro, Elif F. Sen, Achille P Caputi, Miriam CJM Sturkenboom. (Netherlands) |

**CNS Drugs and Health Outcomes**  
(Room 18/19)

**Moderators:** Paul Stang, FISPE, & Edward Bortnickach

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
</tr>
</thead>
</table>
| 1:30pm | **Atypical Antipsychotic Use and Risk of Fracture in Persons with Parkinson’s Disease** [47]  
David D Dore, Amal N Trivedi, Vincent Mor, Joseph H Friedman, Kate L. Lapane. (United States) |
| 1:45pm | **Risk of Ischemic Events among Patients with Parkinson’s Disease Using Dopamine Agonists** [48]  
Maurits E L Arbouw, Kris L L Movig, Henk Jan Guchelaar, Kees Neef, Toine CG Egberts. (Netherlands) |
| 2:00pm | **Taking Low Dose Aspirin Is Associated with More Stable Drug Treatment for Lithium Users** [49]  
Pieter Stolk, Patrick C Souverein, Ingeborg Wilting, Hubert GM Leufkens, Donald F Klein, Stanley I Rapoport, Eibert R Heerdink. (Netherlands) |
| 2:15pm | **ACE Inhibitors Are Associated with Complex Regional Pain Syndrome (CRPS)** [50]  
Marissa de Mos, Bruno HCh Stricker, Frank JPM Huygen, Jeanne P Dieleman, Miriam CJM Sturkenboom. (Netherlands) |
| 2:30pm | **Seizures in a Pediatric Population Treated with Atomoxetine or Stimulant Medications** [51]  
Andrew T McAfee, Joan Landon, Meghan E. Jones, Mark E. Bangs, Nayan Acharya, Kenneth Hornbuckle, Judy Wong. (United States) |
| 2:45pm | **Exploring Channelling Bias of Anti-Epileptic Drugs in Epilepsy Patients in a US Claims Database and a UK General Practice Database** [52]  
Lianna Ishihara Paul, David J Webb, Maneesh Juneja, Ponmani Kanakaraj, John Weil. (United Kingdom) |
AGENDA - MONDAY, AUGUST 18

Respiratory Medications and Health Outcomes (Room 20)
Moderators: Colin Dormouth & Jordi Castellsague

1:30pm
 IMPLEMENTATION - mondays, august 18

 ▶ Long-Acting Beta Agonists and Risk of Death and Asthma Exacerbation [53]
   Tobias Kurth, Heather Norman, Carlos Fernandez Vidaurre, John Seeger. (United States)

1:45pm
 IMPLEMENTATION - mondays, august 18

 ▶ Inhaled Anticholinergic Drugs and Risk of Acute Urinary Retention [54]
   Ana SM Afonso, Katia MC Verhamme, Bruno Ch Stricker, Guy GO Brusselle, Miriam CJM Sturkenboom. (Netherlands)

2:00pm
 IMPLEMENTATION - mondays, august 18

 ▶ Does Asthma Medication Increase the Risk of Dental Caries among Children? [55]
   Régis Blais, Jean-Marc Brodeur, Claudine Laurier, Christophe Bedos. (Canada)

3:00-3:30pm
 Break/Posters/Exhibits (Hall A1)

2:15pm
 IMPLEMENTATION - mondays, august 18

 ▶ Palivizumab Utilization and Compliance with Recommendations in Florida [56]
   Christian Hampp, Almut G Winterstein, Arwa Saidi, Huazhi Liu. (United States)
   Student Award Recipient – Best Drug Utilization Abstract

2:30pm
 IMPLEMENTATION - mondays, august 18

 ▶ Treatment and Survival in Patients with Pulmonary Arterial Hypertension (PAH) [57]
   Hilal Maradit Kremers, Joshua P Slusser, Christopher G Scott, Paola Primasteya, Michael D McGoon. (United States)
3:30-5:00pm

**CONCURRENT SESSIONS: SYMPOSIA**

**SYMPOSIUM: A European Network of Centres for Pharmacovigilance and Pharmacoepidemiology (ENCePP)** [58] (Auditorium 10)

- Noel A Wathion, Stella Blackburn, Xavier Kurz, Ingemar R Persson, Yola Moride, Miriam CJM Sturkenboom (Sweden)


- Bruno Flamion, Michael Arrighi, Reed Johnson, Susana Perez (United States)

**SYMPOSIUM: Recent Advances in Statistical Methods for Analyzing Observational Cohort Studies: New Opportunities for Pharmaco-Epidemiology** [60] (Auditorium 12)

- M Abrahamowicz, R Cook, P Gustafson, P Royston, W Sauerbrei (Canada)

**SYMPOSIUM: Practical Issues in Measuring Cessation and Re-Initiation of Drug Use in Databases** [61] (Room 18/19)

- Morten Andersen, M Alan Brookhart, Robert J Glynn, Henrik Stovring, Til Stürmer (United States)

**SYMPOSIUM: Biological Medicinal Products: Special Considerations for Pharmacoepidemiology and Risk Management** [62] (Room 20)

- Wei Dong, Judith K Jones, HGM Leufkens, Joanna F Haas (United States)

5:00-6:00pm

**ISPE Council Meetings**
Open to all interested participants.

- **Government/Regulatory Council** (Room 16)
- **Academic Council** (Room 17)
- **Industry Council** (Room BV2)
- **EuroDURG General Assembly** (Room 20)

7:00-8:30pm

**PDS Editorial Board** (Helsinki Room, Radisson SAS Scandinavia Hotel)
- By Invitation

7:00-10:00pm

**Student Social Event – A Night Out in Copenhagen**
Open to all students.
Organized by the ISPE Student Council
AGENDA - Tuesday, August 19

7:30-8:15am
Poster Session B Set-up (Hall A1)

7:30am-6:00pm
Registration (Auditorium Foyer)

7:30am-5:00pm
Speakers’ Ready Room (Room 7)

8:00am-6:00pm
Exhibits/Posters (Hall A1)

8:00-9:30am
PLENARY SESSION (Auditorium 10-12)
Hot Topics Session: Adverse Effects of Antidiabetic Therapy

Chair:
Stephen Evans

Speakers:
Jerry Avorn, FISPE
Stephen Evans
John Ioannidis

Copenhagen, Denmark

Cutting edge epidemiology contributing to the discovery and development of safe and effective medicines

We are a global team of epidemiologists and other professionals that bring population-based evidence on disease and treatment to influence decision-making from drug discovery through development to medical practice. By designing, analyzing, and interpreting observational information from a public health perspective we play an important role in bringing new medicines to the market. The breadth of our responsibilities includes:

- Analyzing the occurrence and distribution of diseases, including underlying disease process
- Determining the burden of illness and unmet medical need
- Exploring traditional and new risk factors for diseases
- Evaluating the effect of treatment in the real world, including beneficial effects, patterns of drug uses and adverse events
- Detecting opportunities for possible new drug uses and new paths of drug development

Please visit our website at http://epidemiology.gsk.com/organization.html to find out more detailed information about Worldwide Epidemiology at GlaxoSmithKline.

Developing talent through equality of opportunity
9:30-10:15am

**ANNUAL MEETING OF ISPE MEMBERS & AWARDS CEREMONY** (Auditorium 10-12)

- Open to all participants.

**Annual Meeting of ISPE Members**

- Yola Moride, FISPE, ISPE President
- Corinne de Vries, ISPE Vice President Finance

**Awards Ceremony**

**ICPE 2008**

- Jens Peter Balling, Chair, Local Host Committee
- Jesper Hallas, Chair, 2008 Scientific Program Committee

**Student Awards**

- Presented by Jesper Hallas, Chair, 2008 Scientific Program Committee

**Best Drug Utilization Abstract:** Christian Hampp, University of Florida, Palivizumab Utilization and Compliance with Recommendations in Florida [56]

**Best Methods Abstracts:** Helga Gardarsdottir, Utrecht University, An Algorithm To Identify Antidepressant Users with a Diagnosis of Depression from Prescription Data [1]

**Third Best Abstract:** Annette Østergaard Jensen, Aarhus University Hospital, Use of Photosensitizing Diuretics and Risk of Skin Cancer: A Population Based Case Control Study [247]

**Second Best Abstract:** Adela Corina Boila, University of Medicine and Pharmacy Targu Mures, Diuretics and the Risk of Acute Pancreatitis: A Population-Based Case-Control Study [540]

**Edlavitch Award (Best Abstract):** Jochem G. Gregoor, Utrecht University, Polymorphisms of the LEP- and LEPR Gene and Obesity in Psychiatric Patients Using Antipsychotic Medication [463]

**Induction of ISPE Fellow (FISPE)**

- Allen A. Mitchell, FISPE, Chair, Fellowship & Awards Committee

Inductees:

- Andrzej Czarnecki, FISPE
- Jean-Pierre Grégoire, FISPE
- Sonia Hernandez-Diaz, FISPE

**ISPE-PDS Prizes for Best Papers Published in PDS Volume 16 (2007)**

- Presented by Ronald D. Mann, FISPE, Editor-in-Chief, Brian Strom, FISPE, Regional Editor for the Americas, Joerg Hasford, Regional Editor for Europe, and Richard Hughes, Managing Editor, Pharmacoepidemiology & Drug Safety (PDS)
11:00am-12:30pm
CONCURRENT SESSIONS – CONTRIBUTED PAPERS

**Surprising Determinants and Outcomes of Therapy** (Auditorium 10)

**Moderators:** Alec Walker, FIPSE, & Walter Straus

**11:00am**
- **Stopping Hormone Replacement Therapy (HRT). What's Next?** [235]
  Stefan Vegter, Pieteren Kolling, Marjolein Toben, Paul B van den Berg, Lolkje TW de Jong-van den Berg. (Netherlands)

**11:15am**
- **Contraceptive Efficacy of Oral Contraceptives under Real Life Conditions: The Impact of a 24-Day Regimen on Contraceptive Effectiveness** [236]
  Juergen Dinger, Anita Assmann, Mathias Altmann. (Germany)

**11:30am**
- **Setting Prices for Generic Medications: A Survey of Patients Perceptions** [237]
  Niteesh K Choudhry, Emily Cox, Michael A Fischer, Jyotsna Mehta, William H Shrank. (United States)

**11:45am**
- **Prescribing Quality Indicators for Cardiovascular Treatment in Type 2 Diabetes: Should We Assess Treatment Decisions over Time?** [238]
  Jaco Voorham, Flora M Haaijer Ruskamp, Bruce H Wolfenbuttel, Ronald P Stolk, Petra Denig, GIANTT Group. (Netherlands)

**12:00pm**
- **Pharmacologically Inappropriate Prescriptions for Elderly Patients in General Practice – How Common? Baseline Data from the Prescription Peer Academic Detailing (RX-PAD) Study** [239]
  Mette Brekke, Rognstad Sture, Joerund Straand, Kari Furu, Svein Gjelstad, Trine Bjoerner, Ingvild Dalen. (Norway)

**12:15pm**
- **The Effect of Altitude on Erythropoietin Dosing and Achieved Hematocrit Levels in End-Stage Renal Disease** [240]
  M Alan Brookhart, Sebastian Schneeweiss, Jerry Avorn, Brian D Bradbury, Kenneth J Rothman, Jyotsna Mehta, Michael Fischer, Wolfgang Winkelmayr. (United States)

**11:00am-12:30pm**
DUR SIG SPECIAL POSTER SESSION

**Resources for Cross-National Comparison of Drug Utilization Data: Results of a SIGDUR/EuroDURG Survey** (Hall A1)

*Special poster session. Note: these posters will be up Monday-Wednesday*

**Co-Chairs:** Monique Elseviers, Vera Vlahovic-Palcevski & Katrin Janhansen

**Theoretical Methods** (Auditorium II)

**Moderators:** Gergana Zlateva & Henrik Sørenson

**11:00am**
- **Doubly Robust Estimation under Realistic Conditions of Model Misspecification** [241]
  Michele L Jonsson Funk, Daniel Westreich. (United States)

**11:15am**
- **Performance of Disease Risk Scores in Case-Control Studies** [242]
  Patrick G Arbogast, Lisa Kaltenbach, Wayne A Ray. (United States)

**11:30am**
- **Propensity Score Calibration in the Absence of Surrogacy** [243]
  Mark Lunt, Robert J Glynn, Kenneth J Rothman, Jerry Avorn, Til Stürmer. (United States)

**11:45am**
- **Using Tree-Based Survival Analysis To Identify Risk Factors Associated with the Onset of Cardiovascular Events among SLE Patients** [244]
  Liping Huang, Karen Wilcock. (United States)

**12:00pm**
- **A Method for Estimating the Completeness of a Literature Search** [245]
  Charlie H Goldsmith, Gary Foster. (Canada)

**12:15pm**
- **A Consideration on Sample Size Determination for Stratified Case-Cohort Studies** [246]
  Akira Wakana, Kiyoshi Kubota. (Japan)
AGENDA - TUESDAY, AUGUST 19

Cancer (Auditorium 12)
Moderators: Laurel Habel and Soren Friis

11:00am
**Use of Photosensitizing Diuretics and Risk of Skin Cancer: A Population Based Case Control Study [247]**
Annette O Jensen, Henrik F Thomsen, Anne B Olesen, Henrik T Sorensen, Margaret R Karagas. (Denmark)

**Student Award Recipient – Third Best Abstract**

11:15am
**Occurrence of Lymphoma among Patients with Atopic Dermatitis and/or Treated with Topical Immunosuppressants in the United Kingdom [248]**
Felix M Arellano, Alejandro Arana, Charles E Wentworth III, Eulogio Conde, Carlos Fernandez-Vidaurre, Raymond Schlienger. (Spain)

11:30am
**Topical Treatments for Atopic Dermatitis and Comparative Risk of Lymphoma [249]**
Sebastian Schneeweiss, Mike Doherty, Shao Zhu, Donnie Funch, Raymond G Schlienger, Carlos Fernandez Vidaurre, John D Seeger. (United States)

1:45am
**Short-Term Exposure to Pioglitazone Is Not Associated with an Increased Risk of Cancer at the 10 Most Common Sites [250]**
Assiamira Ferrara, Laurel A Habel, James D Lewis, Stephen K Van Den Eeden, Brian L Strom, Charles P Quesenberry. (United States)

12:00pm
**Recombinant Human Bone Morphogenetic Protein-2 and Pancreatic Cancer: A Retrospective Cohort Study [251]**
Gregory S Cooper, Daniel Mines, Yun Gu. (United States)

12:15pm
**Use of Thiazolidinediones for Elderly Diabetic Patients with Cardiac Disease [252]**
Jong-Mi Seong, Nam-Kyong Choi, Sun-Young, Jung, Yoo-soo Chang, Ye-Jee Kim, Byung, Joo Park. (Korea)
Investigations in Pharmacovigilance (Room 18/19)

**Moderators**: M. Miles Braun, FISPE, & Paul Beninger

**11:00am**
- **Tramadol Dependence: A Survey of Spontaneously Reported Cases in Sweden [253]**
  - Micaela Tjaderborn, Anna K Jonsson, Johan Ahlner, Staffan Hagg. (Sweden)

**11:15am**
- **Kawasaki Disease after Vaccination: Reports to the Vaccine Adverse Event Reporting System (VAERS) 1990-2007 [254]**
  - Wei Hua, Hector S Izurieta, Barbara Slade, Ermias Belay, Penina Haber, Rosemary Tiernan, Emily Jane Woo, John Iskander, M Miles Braun, Robert Ball. (United States)

**11:30am**
- **Combined Pioglitazone-Insulin Use: Analysis from the Pioglitazone Prescription Event Monitoring Study [255]**
  - Rachna Kasliwal, Victoria Cornelius, Lynda V Wilton, Saad AW Shakir. (United Kingdom)

**11:45am**
- **Photochemical and Other Molecular Characteristics and the Risk of Drug-Related Photosensitivity [256]**
  - BM Verdel, PC Souverein, RHB Meyboom, HGM Leufkens, ACG Egberts. (Netherlands)

Potpourri I (Room 20)

**Moderators**: Ron Herings, FISPE, & Hedi Schelleman

**11:00am**
- **Comparative Effectiveness of Osteoporosis Drugs for Nonvertebral Fracture Prevention [259]**
  - Suzanne M Cadarette, Jeffrey N Katz, M Alan Brookhart, Til Sturmer, Margaret R Stedman, Daniel H Solomon. (United States)

**11:15am**
- **Definition of Chronic Kidney Disease by Creatinine Based Methods May Be Strongly Misleading in Patients with Diabetes [260]**
  - Dietrich Rothenbacher, Qiu-Li Zhang, Nuria Riera-Guardia, Wolfgang Koenig, Hermann Brenner. (Germany)

**11:30am**
- **Cohort Effect or Selective Prescribing by Indication in the Prescription of New Atypical Antipsychotic in Schizophrenia? [261]**
  - L Abenhaim, B Astruc, H Verdoux, B Falissard, J Benichou, M Rossignol, P Blin, F Depont, F Rouillon. (France)

**11:45am**
- **Mortality and Long-Lasting Sequelae in Patients with Severe Cutaneous Adverse Reactions [262]**
  - M Mockenhaupt, P Sekula, JC Roujeau, A Sidoroff, S Kardaun, Y Liss, M Bounoua, for the RegiSCAR Study Group. (Germany)

---

**12:00pm**
- **GPRD for Proactive Safety Surveillance of a Rare Outcome: The Example of Bone Marrow Fibrosis among Patients with ITP [257]**
  - Diego Wyszynski, Chuck Wentworth, Steven Cha, Victor Gastanaga, George

**12:15pm**
- **Anaphylaxis after Measles, Mumps and Rubella (MMR) Vaccine during 2006-7 in the U.S. [258]**
  - Hector S Izurieta, Steven K Tobler, Patrick M Garman, Wei Hua, Penina Haber, John Iskander, M Miles Braun, Robert Ball. (United States)

---

**12:00pm**
- **Impact of Severe Premenstrual Disorders on Work, Daily Life, Social Relations, and Quality of Life: Preliminary Results of a Multinational Follow-Up Study [263]**
  - Anita Assmann, Juergen Dinger, Anna Filonenko, Do Minh Thai, Lothar Heinemann. (Germany)

**12:15pm**
- **Safety Assessment after Recall of Haemophilus influenzae Type B (Hib) Vaccine — United States, 2007-2008 [264]**
  - WT Huang, S Chang, ER Miller, EJ Woo, AR Hoffmaster, JE Gee, T Clark, J Iskander, R Ball, K Broder. (United States)
AGENDA - TUESDAY, AUGUST 19

12:30-2:00pm
Lunch/Poster Session B/Exhibits (Hall A1)
   - Sponsored by i3 Drug Safety
Poster Walk:  ▶ Medicines in Pregnancy

ISPE Committee Meetings
   • Open to all participants.
   • Lunches will be available in meeting rooms
   ▶ Global Development Committee (Room 16)
   ▶ Membership Committee (Room 18A)
   ▶ Publications Committee (Room 18B)
   ▶ Bylaws and Policies Committee (Room 23)

2:00-3:30pm
CONCURRENT SESSIONS – CONTRIBUTED PAPERS

Diabetes: Treatment Related Risks and Benefits (Auditorium 10)
   Moderators: Donald Miller & Hubert GM Leufkens, FISPE

2:00pm
   ▶ Cardiovascular Disease Risks with Rosiglitazone and Pioglitazone Use in U.S. Veterans [266]
      Donald R Miller, Cindy Christiansen, Madhuri Palnatti, Jean-Philippe LaFrance, Leonard Pogach, Francesca Cunningham. (United States)

2:15pm
   ▶ Determinants of Stopping Treatment with Oral Antidiabetic Drugs in Daily Practice [267]
      Fernie JA Penning van Beest, Sjoukje van der Bij, Joelle A Erkens, Heather Falvey, Ron MC Herings. (Netherlands)

2:30pm
   ▶ Risk Factors for Thiazolidine-Related Peripheral Edema [268]
      Patricia Tennis, Neil Roskell, Elizabeth Andrews, Kenneth J Rothman. (United States)

2:45pm
   ▶ Assessing Returns from Recommended Medication Use by US Medicare Beneficiaries with Diabetes [269]
      Bruce Stuart, Linda Simoni-Wastila, Lirong Zhao, Jalpa Doshi. (United States)

3:00pm
   ▶ ACE-Inhibitors and Angiotensinogen M235T Variant Interact in Type 2 Diabetes Mellitus Risk [270]
      Mark Eijgelsheim, Olaf H Klungel, Bruno H Stricker. (Netherlands)

3:15pm
   ▶ Reduced Risk of Hypoglycaemia in Analogue Compared with Human Insulin: An Observational Study in the UK [271]
      Annie Hutchison, David Russell-Jones, Victoria Hordern, Corinne S de Vries. (United Kingdom)
Quality and Appropriateness of Therapeutic Use (Auditorium II)

**Moderators:** Lynn Bosco & Steven Bailey

**2:00pm**
**What Impact Has Restrictions on Use of COX 2 Inhibitors Had in Ireland? [275]**
Kathleen Bennett, Mary Teeling, John Feely. (Ireland)

**2:15pm**
**Effect of Regulatory Warnings on Antipsychotic Prescribing for Nursing Home Residents with Dementia [273]**
Tobias Gerhard, Judith Lucas, Mark Olsson, Donald Hoover, Ece Kalay, Stephen Crystal. (United States)

**2:30pm**
**Trends in Treatment for Pediatric Depression – Before and after FDA Advisory on Risk of Suicidality with Antidepressants [274]**
Shih Yin Chen, Sengwee Toh. (United States)

Cardiovascular Drugs and Outcomes (Auditorium 12)

**Moderators:** Nicholas Moore, FISPE, & Christina Varas Lorenzo

**2:00pm**
**A Cohort Study of Venous Thromboembolism, Anticoagulant Use, and Subsequent Cardiovascular Disease [278]**
Robert J Glynn, Til Sturmer, Helen Mogan, Sebastian Schneeweiss. (United States)

**2:15pm**
**Association Between Calcium Channel Blockers and Gingival Hyperplasia [283]**
Gaganpreet Kaur, Katia MC Verhamme, Jeanne P Dielemann, Ann Vanrolleghem, Eva M van Soest, Bruno HCh Stricker, Miriam CJM Sturkenboom. (Netherlands)

**2:30pm**
**Preadmission Statin Use and One-Year Mortality Among Intensive Care Patients [280]**
Steffen Christensen, Reimar W Thomsen, Martin B Johansen, Lars Pedersen, Henrik T Sorensen. (Denmark)

**2:45pm**
**Withdrawal of Endothelium Affecting Drugs and Risk of Subarachnoid Hemorrhage (SAH) [281]**
R Risselada, H Straatman, R Herings, M Sturkenboom. (Netherlands)
AGENDA - TUESDAY, AUGUST 19

Databases: Truth or Consequences? (Room 18/19)
Moderators: Susan Oliveria & Nancy Santanello

2:00pm

Determining the Predictive Value of Read Codes To Identify Incident Acute Myocardial Infarction in the General Practice Research Database [284]
Tarek A Hammad, Mara A McAdams, Andrea Feight, Solomon Iyasu, Gerald J Dal Pan. (United States)

2:15pm

Positive Predictive Value of Computerized Medical Records for Uncomplicated Upper Gastrointestinal Ulcer [285]
Andrea Margulis, Luis A Garcia Rodriguez, Sonia Hernandez-Diaz. (United States)

2:30pm

One Question, Several Countries: Understanding Health Systems and Standardising Recording Habits in Primary Care Databases in France, Germany, Italy and the UK [637]
Andrew Maguire, Marie-Sophie Schwalm. (United Kingdom)

2:45pm

Identification of Mother-Infant Pairs in the German Pharmacoepidemiological Database [287]
Elke Scharnetzky, Frank Andersohn, Ingo Langner, Edeltraut Garbe. (Germany)

3:00pm

A Systematic Approach for Unassigned ICD-9 Codes in a Health Insurance Claims Database [288]
Hoa V Le, Kathleen J Beach. (United States)

3:15pm

Developing a Model Predicting Poor Outcome in Chronic Obstructive Pulmonary Disease [289]
Stuart Schembri, Anderson William, Winter John, Winter Janet, MacDonald Thomas. (United Kingdom)

Advancing science. Serving patients.

Amgen, a biotechnology pioneer, discovers, develops and delivers innovative human therapeutics. Our medicines have helped millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses.

With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.

To learn more about Amgen, our vital medicines, our pioneering science, and our career opportunities, visit www.amgen.com/careers.

Pioneering science delivers vital medicines™
www.amgen.com/careers

As an EEO/AA employer, Amgen values a diverse combination of perspectives and cultures. M/F/D/V.
AGENDA - TUESDAY, AUGUST 19

Potpourri II & Late Breakers (Room 20)
Moderators: Sean Hennessy, FISPE, & Eibert Heerdink

2:00pm
- Use of Phthalate-Containing Medications and Urine Phthalate Concentrations [291]
  Sonia Hernández-Díaz, Allen A Mitchell, Russ Hauser. (United States)

2:15pm
- Peginterferon alfa-2a Treatment in 2101 HCV Infected Patients: Quality Criteria and Results from the French HEPATYS Cohort [290]
  Cecile Hayem, Marc Bourliere, Marie Odile Barbaza, Alexandrina Pinta, Francois Montestrucc, Muriel Vray. (France)

2:30pm
- Anti-Epileptic Medication Drug Formulation Changes and Their Relationship to Outcomes (Ambulance, Emergency Department, and Inpatient Events) [292]
  KL Rascati, MJ Johnsrud, KM Richards, TA Mann. (United States)

2:45pm
- Death and Renal Dysfunction with Aprotinin Use in Cardiac Surgery: A Meta-Analysis of Observational Studies [293]
  Joshua J Gagne, Donald E Griesdale, Sebastian Schneewess. (United States)

3:00pm
- A New Approach to Pharmacovigilance in Pregnancy in Australia [294]
  Lyn Colvin, Carol Bower, Linda Slack-Smith. (Australia)

3:15pm
- Comparative Effects of Anti-Fibrinolytic Drugs in Cardiac Surgery: Updated Cochrane Review of Mortality [295]
  D Henry, P Carless, A Laupacis, D Fergusson. (Canada)

Specialization and scientific depth that effectively manage risk and change.

i3 Drug Safety provides the data and services to meet regulatory requirements and support risk management programs for drugs, devices, and biologics throughout the product development and commercialization lifecycle. Our proven expertise cultivates a safer healthcare experience for all.

www.i3drugsafety.com

epidemiology
risk management
pharmacovigilance
signal detection

Come visit us in the exhibit hall to learn more about how we can support your product.

The company of specialists.
3:30-4:00pm
Break/Posters/Exhibits (Hall A1)

4:00-5:30pm
CONCURRENT SESSIONS: SYMPOSIA & WORKSHOPS

SYMPOSIUM: The Nordic Countries as a Cohort [296]
(Auditorium 10)
- Henrik T Sørensen, Kari Furu, Morten Andersen, Jaana Martikainen, Ulf Bergman (Norway)

SYMPOSIUM: Selective Prescribing, Frailty, and Healthy-User Effects in Pharmacoepidemiology [297]
(Auditorium 11)
- M Alan Brookhart, Colin Dormuth, Sascha Dublin, Robert J Glynn, Amanda R Patrick, Kenneth J Rothman (United States)

WORKSHOP: Publishing in Pharmacoepidemiology [298]
(Auditorium 12)
- Brian L Strom, Ronald Mann, Joerg Hasford (United States)

SYMPOSIUM: Identifying Potential Safety Concerns in Claims and Electronic Health Record (EHR) Databases [299]
(Room 18/19)
- Nancy Santanello, Susan Sacks, Andrew Bates, A Lawrence Gould, Patrick Ryan, Paul Stang, Alexander Walker (United States)

SYMPOSIUM: Linking Pharmacoepidemiology with Pharmacogenomics: Opportunities To Incorporate Genomics into Pharmacoepidemiology Studies [300]
(Room 20)
- Andrew N Freedman, Leah B Sansbury, Geoffrey Liu (United States)

5:30-6:30pm
Special Interest Group (SIG) Meetings
Open to all participants.
- Medications in Pregnancy SIG (Room 16)
- Database SIG (Room 17)
- Drug Utilization Research SIG (Room 20)
- Biologics (Room 21)
- Molecular Epidemiology/Pharmacogenetics SIG (Room 23)

7:30pm-Midnight
Evening at the Langelinie Pavillonen
- Admission is by badge or ticket.
- Cash bar (no credit cards)

Join us for a relaxing evening of camaraderie, food, and music at Langelinie Pavillonen. The British life-style magazine, Wallpaper, acclaimed Langelinie Pavillonen as being ‘one of the most spectacular spots in the city. It’s a popular venue for fashion and media parties.’ Music will be provided by Copyright, one of Denmark’s best dance bands, and feature Christina Boelskifte.

Transportation. Tour boats will shuttle between the ICPE pick up/drop off point at Nyhavn/Havnegade and the restaurant beginning at 7:00pm. The first departure from the restaurant to Nyhavn/Havnegade will be at 9:30pm; the last at 12:30am. [NOTE: A one-way ride takes about a 25-minutes. Bring a sweater or jacket; it can be cool on the water at night.]
Pharmacoepidemiology
AND DRUG SAFETY

Official Journal of the International Society for Pharmacoepidemiology

Editor-in-Chief: Professor Ronald D. Mann

Pharmacoepidemiology and Drug Safety provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology.

* Free online access for ISPE members via the society website
* Latest Impact Factor: 2.475 (JCR 2007)

A selection of the top-downloaded papers from the 2007 Volume (16)

- Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present
  David L. McClure, Robert J Valuck, Morton Glanz et al.
  Volume 16, Issue 2, Pages 132 – 143

- Asthma drug use and the development of Churg-Strauss syndrome (CSS)
  Leslie R. Harrold, M. Kay Patterson, Susan E. Andrade et al.
  Volume 16, Issue 6, Pages 620 – 626

- Coronary heart disease outcomes in patients receiving antidiabetic agent
  Andrew T. McAfee, Carol Koro, Joan Landon et al.
  Volume 16, Issue 7, Pages 711 - 725

- Risk of myocardial infarction associated with selective COX-2 inhibitors: Meta-analysis of randomised controlled trials
  Li-Chia Chen, Darren M Ashcroft.
  Volume 16, Issue 7, Pages 762 - 772

- A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes
  Charles M. Gerrits, Mondira Bhattacharya, Shivaji Manthena et al.
  Volume 16, Issue 10, Pages 1065 – 1071

For more information on these top papers and other journal features, please visit

www.interscience.wiley.com/journal/pds

Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2008 Volume: 17 • Frequency: Monthly
AGENDA - WEDNESDAY, AUGUST 20

7:00-8:00am
Poster Session C Set-up (Hall A1)

7:30am-4:30pm
Registration (Auditorium Foyer)

7:30am-3:30pm
Speakers' Ready Room (Hall C)

7:00-8:00am
Exhibits/Posters (Hall B)

8:00am-1:15pm
Exhibits/Posters (Hall B)

8:30am-10:00am
CONCURRENT SESSIONS – CONTRIBUTED PAPERS

Psychotropic Medication in Children (Auditorium 10)
Moderators: Ulf Bergman, FISPE, & Elizabeth Andrews, FISPE

8:30am
▶ Medicine Use for Pain and Psychological Complaints among Children and Adolescents: Trends 1988-2006 [449]
   Anette Andersen, Bjorn E Holstein, Pernille Due, Ebba H Hansen. (Denmark)

8:45am
▶ Psychotherapy Use among Adolescents Prescribed Antidepressants and Antipsychotics [450]
   Tami Mark, Stacey R Long. (United States)

9:00am
▶ Use of Antidepressants in Children and Adolescents [451]
   Dominique Milea, Nicolas Despiegel, Patrice Verpillat, Gérard Duru. (France)

9:15am
▶ Impact of Comorbid Disruptive Disorders on Pharmacotherapy for Attention Deficit/Hyperactivity Disorder in Publicly Insured U.S. Youth [452]
   Julie M Zito, Satish Valluri, Sarah D Hundley, Daniel J Safer, James F Gardner, Mark Maneval, James J Korelitz, Diane J McNally, Perdita Taylor-Zapata, Donald R Mattison. (United States)

9:30pm
▶ Treatment Persistence among Youths Newly Diagnosed with Attention Deficit/Hyperactivity Disorder (ADHD) [453]
   CY Chen, AG Winterstein. (United States)

9:45pm
▶ Mortality Following Antiepileptic Drugs in Paediatrics with Epilepsy – Preliminary Results Using the General Practice Research Database (GPRD) [454]
   Ruth Acker, Frank MC Besag, Ian CK Wong. (United Kingdom)

Potpourri III (Auditorium II)
Moderators: Morten Andersen & Walter Straus

8:30am
▶ Role of Dose-Potency in the Prediction of Risk of Myocardial Infarction Associated with Nonsteroidal Anti-Inflammatory Drugs in the General Population [455]
   Luis A Garcia Rodriguez, Stefania Tacconelli, Paola Patrignani. (Spain)

8:45am
▶ National Register Study on Atrial Fibrillation, Ischemic Stroke, and Myocardial Infarction in Fracture Patients Treated with Oral Bisphosphonates [456]
   Bo Abrahamsen, Pia A Eiken, Kim Brixen. (Denmark)

9:00am
▶ Drug Treated Diabetes and Poor Long Term Glycemic Control Increase the Risk of Hospitalization with Pneumonia: Population-Based Case-Control Study [457]
   Jette B Kornum, Reimar W Thomsen, Anders Riis, Hans-Henrik Lervang, Henrik C Schonheyder, Henrik T Sørensen. (Denmark)

9:15am
▶ Postmenopausal Hormone Therapy and Coronary Heart Disease: Adjusting for Imperfect Adherence [458]
   Sengwee Toh, Sonia Hernandez-Diaz, Miguel A Hernan. (United States)

9:30pm
▶ Instrumental Variable Analysis for Estimation of Absolute and Relative Treatment Effects with Binary Outcomes [459]
   Jeremy A Rassen, Sebastian Schneeweiss, Robert J Glynn, Murray A Mittleman, M Alan Brookhart. (United States)

9:45pm
▶ Assessment of Brookhart’s Instrumental Variable Approach in Pharmacoepidemiology: The Impact of Using a Weak Instrument [460]
   Raluca Ionescu-Ittu, Michal Abrahamowicz, Joseph A Delaney. (Canada)
Anti-Psychotic Treatment: Metabolic Outcomes and Death
(Auditorium 12)

Moderators: Eibert Heerdink & Jessica Jalbert

8:30am

- The Prevalence and Costs of Metabolic Conditions among Patients with Bipolar Disorders as Compared to Matched Controls [461]
  Tami L. Mark, Franca Centorrino, Alessandra Talamo, Kelly Oh, Jane Chang. (United States)

8:45am

- Risk of Developing Diabetes among Adolescents with Bipolar Disorder or Schizophrenia [462]
  Cheryl Enger, Meghan E. Jones, Ludmila Kryzhanovskaya, Michael Doherty, Andrew T McAfee. (United States)

9:00am

- Polymorphisms of the LEP- and LEPR Gene and Obesity in Psychiatric Patients Using Antipsychotic Medication [463]
  Jochem G Gregoor, Jan van der Weide, Hans Mulder, Harold JGM van Megen, Antoine CG Egberts, Eibert R Heerdink. (Netherlands)

  Student Award Recipient – Edlavitch Award (Best Abstract)

9:15am

- Metabolic Testing after the FDA Warning on Atypical Antipsychotic Drugs and Diabetes Risk [464]
  Elaine H Morrato, John W Newcomer, Siddhesh Kamat, Onur Baser, James Harnett, Brian Cuffel. (United States)

9:30pm

- Use of Antipsychotic Polypharmacy among Patients with Schizophrenia and Risk of Death [465]
  Christiane Gasse, Lone Baandrup, Merete Nordentoft, Birte Y Glenthøj, Henrik Lublin, Vibeke Dahl Jensen, Lars Krosggaard Thomsen, Jan Poulsen, Preben B Mortensen. (Denmark)

9:45pm

- Comparative Mortality Associated with Ziprasidone vs. Olanzapine in Real-World Use: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC) [466]
  Brian L. Strom, Gerald Faich, Sybil Eng, Robert Reynolds, Ralph D’Agostino, Jeremy Ruskin, John Kane. (United States)

The Worlds A’ Changing: International Comparisons of Drug Safety and National Insurance Policy (Room 18/19)

Moderators: Judith Jones, FISPE, & Patrick Waller

8:30am

- Timing of Safety-Related Labeling Changes and Marketing Withdrawals for New Molecular Entities (1991-2007) [467]
  Mara A McAdams, Judy A Staffa, Solomon Iyasu, Gerald J Dal Pan. (United States)

8:45am

- A Drug’s Life Cycle and Communication of Safety Issues [468]
  Peter Mol, Jonie de Vries, Sabine Straus, Pieter de Graeff, Flora Haaijer-Ruskamp. (Netherlands)

9:00am

- Cardiovascular Risk Factors and Medical History of Cardiovascular (CV) and Gastrointestinal (GI) Event among Etoricoxib Users in the United Kingdom (UK) before and after the COX-2 Urgent Safety Restriction [469]
  Bing Cai, Douglas Watson. (United States)

9:15am

- Predictors of Medicare Part D Enrollment: The Experience of Medicare Drug Demonstration Participants with Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS) [470]
  Jennifer M Polinski, Penny E Mohr, Lorraine Johnson. (United States)

9:30pm

- The Effect of Transitioning to Medicare Part D Drug Coverage in Seniors Dually Eligible for Medicare and Medicaid [471]
  William H Shrank, Amanda R Patrick, Alex Pedan, Jennifer M Polinski, Laleh Varesteh, Raisa Levin, Nan Liu, Sebastian Schneeweiss. (United States)

9:45pm

- The Effect of Prescription Drug Policy Changes on Mental Health Service Use in British Columbia [472]
  Sebastian Schneeweiss, Amanda R Patrick, Colin R Dormuth, Malcolm Maclure, Claire F Canning, Philip S Wang. (United States)
AGENDA - WEDNESDAY, AUGUST 20

The Spectrum of Anti-Infectives (Room 20)
Moderators: Jan Willem van der Velden, FISPE, & Zdravko Vassilev

8:30am
- Antibiotic Prescribing for Otitis Media in Children in UK Primary Care: Have the National Guidelines Affected GP Prescribing Practice? [624]
  Paula L Thompson, Ruth Gilbert, Paul F Long, Sonia Saxena, Mike Sharland, Ian CK Wong. (United Kingdom)

8:45am
- Use of Fluoroquinolones and the Risk of Methicillin Resistant Staphylococcus Aureus (MRSA) [474]
  Katia MC Verhamme, Marie Christine De Smet, Paul Jordens. (Belgium)

9:00am
- Effect of Antibiotics for Otitis Media on Mastoiditis in Children: Retrospective Cohort Study Using the UK General Practice Research Database [475]
  Paula L Thompson, Ruth Gilbert, Paul Long, Sonia Saxena, Mike Sharland, Ian Wong. (United Kingdom)

9:15am
- Adherence to Hepatitis C Virus Therapy and Early Virologic Outcomes [476]
  V Lo Re III, V Amorosa, R Localio, R O’Flynn, V Teal, Z Dorey-Stein, J Kostman, R Gross. (United States)

9:30am
- Antibiotics for Upper Respiratory Infections [477]
  Sharon B Meropol, Zhen Chen, Joshua P Metlay. (United States)

9:45am
- Pre- and Post HAART Prevalence, Incidence, and Type-Specific HPV Persistence among HIV-Positive Adolescents [478]
  Sadeep Shrestha, Laura H Bachmann, Craig M Wilson, Mirjam C Kempf. (United States)

10:00-10:30am
Break/Posters/Exhibits (Hall A1)

10:30am-Noon

CONCURRENT SESSIONS: SYMPOSIA & WORKSHOPS

SYMPOSIUM: Understanding Fetal Risks of Antihypertensive Medication Use During Pregnancy [479] (Auditorium 10)
- William O Cooper, Alissa R Caton, Lolkje TW de Jong-van den Berg, Allen A Mitchell (United States)

WORKSHOP: Instrumental Variable Methods in Pharmacoepidemiology [480] (Auditorium II)
- M Alan Brookhart, Jeremy Rassen, Sebastian Schneeweiss (United States)

- Patricia Saddier, Susana Perez-Gutthann, Annette Stemhagen, Joanna Haas (United States)

SYMPOSIUM: Benefit-Harm Modelling: What Is This and What Can It Contribute to Pharmacovigilance? [482] (Room 18/19)
- Tjeerd P van Staa, Larry D Lynd, Hubert GM Leufkens, June Raine, Hans Petri (United Kingdom)

SYMPOSIUM: Monitoring the Introduction of New Drugs: Methods Focusing on Safety, Costs, and Appropriate Use [483] (Room 20)
- Petra Denig, Lars I Gustafsson, Ken Paterson, Bjorn Wettermark (Sweden)

Noon-1:30pm

Lunch/Poster Session C/Exhibits (Hall A1)
Poster Walks:
- Databases
- Molecular Epidemiology/Pharmacogenetics
- Medicines in Pregnancy/Birth Defects

ISPE Board of Directors Luncheon (Bella Vista Restaurant–BV 4/5)
(Open to ISPE members; notify staff if you plan to attend)

1:30-2:30pm

INVITED PLENARY (Auditorium 10-12)

Pharmacoepidemiology: A Regulator’s Perspective
Hubert GM Leufkens, FISPE, Chair of Dutch Medicines Evaluation Board
AGENDA - WEDNESDAY, AUGUST 20

2:30-4:00pm
PLENARY SYMPOSIUM:
SELF-CONTROLLED DESIGNS [484]
(Auditorium 10-12)

Co-Chairs:
Kenneth J Rothman, FISPE
Sonia Hernandez Diaz, FISPE

Speakers:
C. Paddy Farrington
Samy Suissa
Jesper Hallas

4:00-4:30pm
THE FINAL WORD (Auditorium 10-12)

Poster Awards
Lolkje T. de Jong van den Berg, Chair, Poster Awards Committee

ICPE 2009 - Providence, Rhode Island
Kate Lapane, FISPE, Chair, 2009 ISPE Scientific Program Committee

4:30-5:30pm
2009 Scientific Program Committee Meeting (Room 16)
Kate Lapane, FISPE, Chair, 2009 ISPE Scientific Program Committee
Open to all participants

Adjournment of ICPE 2008

ICPE 2008
24th Annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management

Rhode Island Convention Center
August 16-19, 2009

Abstract Submission Deadline: February 10, 2009

The online abstract site will be operational by mid-December 2008.
Meeting information will be posted at www.pharmacoepl.org